S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:PIRS

Pieris Pharmaceuticals - PIRS Earnings Date, Estimates & Call Transcripts

$1.68
+0.02 (+1.20%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.67
$1.76
50-Day Range
$1.56
$2.07
52-Week Range
$1.51
$6.15
Volume
141,686 shs
Average Volume
445,889 shs
Market Capitalization
$125.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Earnings Summary

Upcoming
Earnings Date
Nov. 1Estimated
Actual EPS
(May. 11)
-$0.07 Beat By $0.05
Consensus EPS
(May. 11)
-$0.12
Last Year's Q2 EPS
(5/17/2021)
-$0.07
Skip Charts & View Estimated and Actual Earnings Data

PIRS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PIRS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Pieris Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.19)($0.04)($0.12)
Q2 20222($0.20)($0.02)($0.11)
Q3 20222($0.19)($0.02)($0.11)
Q4 20222($0.20)($0.17)($0.19)
FY 20228($0.78)($0.25)($0.52)
Q1 20231($0.22)($0.22)($0.22)
Q2 20231($0.21)($0.21)($0.21)
Q3 20231($0.21)($0.21)($0.21)
Q4 20231($0.22)($0.22)($0.22)
FY 20234($0.86)($0.86)($0.86)

PIRS Earnings Date and Information

Pieris Pharmaceuticals last announced its earnings results on May 11th, 2022. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The firm earned $10.99 million during the quarter, compared to analysts' expectations of $11.31 million. Pieris Pharmaceuticals has generated ($0.58) earnings per share over the last year (($0.58) diluted earnings per share). Earnings for Pieris Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.61) per share. Pieris Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 1st, 2022 based off prior year's report dates.

Pieris Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/1/2022
(Estimated)
        
5/11/2022Q1 2022($0.12)($0.07)+$0.05($0.07)$11.31 million$10.99 million      
3/1/2022Q4 2021($0.30)($0.13)+$0.17($0.13)$4.91 million$8.44 million
11/2/20219/30/2021($0.24)($0.24)($0.24)$7.98 million$4.06 million  
8/4/20216/30/2021($0.20)($0.25)($0.05)($0.25)$8.53 million$3.29 million  
5/17/20213/31/2021($0.17)($0.07)+$0.10($0.07)$6.47 million$15.63 million  
3/29/202112/31/2020($0.24)($0.26)($0.02)($0.26)$3.82 million$1.88 million    
11/4/20209/30/2020($0.13)($0.26)($0.13)($0.26)$8.99 million$2.94 million    
8/10/20206/30/2020($0.17)($0.09)+$0.08($0.09)$7.73 million$11.25 million  
5/11/20203/31/2020($0.17)($0.07)+$0.10($0.07)$9.43 million$13.26 million  
3/13/2020Q4 2019($0.25)($0.11)+$0.14($0.11)$5.20 million$17.27 million    
11/11/2019Q3 2019($0.23)($0.0525)+$0.1775($0.05)$6.28 million$15.13 million    
8/9/2019Q2 2019($0.21)($0.24)($0.03)($0.24)$7.32 million$5.33 million  
5/10/2019Q1 2019($0.18)($0.20)($0.02)($0.20)$7.85 million$8.55 million  
3/18/2019Q4($0.16)($0.21)($0.05)($0.21)$6.92 million$4.91 million  
11/7/20189/30/2018($0.15)($0.11)+$0.04($0.11)$6.16 million$8.35 million
8/9/2018Q2 2018$0.01($0.0040)($0.0140)$13.46 million$11.69 million  
5/10/2018Q1 2018($0.0270)($0.1740)($0.1470)($0.17)$11.39 million$4.15 million
3/9/2018Q4 2017($0.04)$0.17+$0.21$0.17$7.63 million$18.15 million  
11/8/2017Q3 2017($0.21)($0.1590)+$0.0510($0.16)$1.52 million$3.93 million
8/9/2017Q2 2017($0.14)($0.23)($0.09)($0.23)$3.75 million$1.85 million
5/10/2017Q1 2017$0.16($0.19)($0.35)($0.19)$32.30 million$1.34 million
3/22/2017Q4 2016($0.13)($0.16)($0.03)($0.16)$1.10 million$2.73 million
11/9/2016Q3 2016($0.13)($0.14)($0.01)($0.14)$1.12 million$0.79 million
8/10/2016Q2 2016($0.13)($0.14)($0.01)($0.14)$1.08 million$1.07 million
5/11/2016Q1 2016($0.05)($0.10)($0.05)($0.10)$6.40 million$1.25 million
3/22/2016Q4 2015($0.13)($0.07)+$0.06($0.07)$3.27 million$2.14 million
11/11/2015Q3 2015($0.12)($0.10)+$0.02($0.10)$0.23 million$0.42 million
8/12/2015Q2 2015($0.14)($0.12)+$0.02($0.12)$0.25 million$0.16 million
5/13/2015Q1 2015($0.19)($0.13)+$0.06($0.13)$1.00 million$0.22 million












Pieris Pharmaceuticals Earnings - Frequently Asked Questions

When is Pieris Pharmaceuticals's earnings date?

Pieris Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 1st, 2022 based off last year's report dates. Learn more on PIRS's earnings history.

Did Pieris Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Pieris Pharmaceuticals (NASDAQ:PIRS) reported ($0.07) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.12) by $0.05. Learn more on analysts' earnings estimate vs. PIRS's actual earnings.

How can I listen to Pieris Pharmaceuticals's earnings conference call?

The conference call for Pieris Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Pieris Pharmaceuticals's conference call transcript?

The conference call transcript for Pieris Pharmaceuticals's latest earnings report can be read online. Read Transcript

How can I view Pieris Pharmaceuticals's earnings report?

Pieris Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Pieris Pharmaceuticals generate each year?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a recorded annual revenue of $31.42 million.

How much profit does Pieris Pharmaceuticals generate each year?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a recorded net income of -$45.74 million. PIRS has generated -$0.58 earnings per share over the last four quarters.

What is Pieris Pharmaceuticals's EPS forecast for next year?

Pieris Pharmaceuticals's earnings are expected to grow from ($0.63) per share to ($0.61) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:PIRS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.